Use for cannabinoid

Patent metadata

Field	Value
Publication number	US-9168278-B2
Application number	US-66789005-A
Country	US
Kind code	B2
Filing date	Nov 15, 2005
Priority date	Nov 16, 2004
Publication date	Oct 27, 2015
Grant date	Oct 27, 2015

Abstract

The invention relates to the use of one or more cannabinoids in the manufacture of medicaments for use in the treatment of diseases and conditions benefiting from neutral antagonism of the CB, cannabinoid receptor. Preferably the cannabinoid is tetrahydrocannabivarin (THCV). Preferably the diseases and conditions to be treated are taken from the group: obesity, schizophrenia, epilepsy, cognitive disorders such as Alzheimer's, bone disorders, bulimia, obesity associated with type II diabetes (non-insulin dependant diabetes) and in the treatment of drug, alcohol and nicotine abuse or dependency.

First claim

The invention claimed is:

1. A method for the treatment of a disease or condition benefiting from neutral antagonism of the CB 1 cannabinoid receptor by tetrahydrocannabivarin (THCV), which comprises administering to a subject in need thereof a therapeutically effective amount of THCV, wherein the disease or condition is selected from the group consisting of obesity, epilepsy, and obesity associated with type II diabetes (non-insulin dependent diabetes), and wherein the THCV is in a substantially pure or isolated form having a chromatographic purity of greater than 90%, and wherein the THCV is the only cannabinoid administered to the subject.

2. A method for cosmetically beneficial weight loss comprising suppression of appetite in a subject by administering to the subject an effective amount of THCV, wherein the THCV is in a substantially pure or isolated form having a chromatographic purity of greater than 90%, and wherein the THCV is the only cannabinoid administered to the subject.

3. A method as claimed in claim 1 , wherein the THCV is in a synthetic form.

4. A method as claimed in claim 1 , wherein the THCV is administered together with one or more pharmaceutically acceptable carriers, excipients or diluents.

5. A method as claimed in claim 1 , wherein the THCV is in a substantially pure or isolated form having a chromatographic purity of greater than 95%.

6. A method as claimed in claim 1 , wherein the THCV is in a substantially pure or isolated form having a chromatographic purity of greater than 98%.

7. A method as claimed in claim 1 , wherein the THCV is in a substantially pure or isolated form having a chromatographic purity of greater than 99%.

8. A method as claimed in claim 1 , wherein the THCV is in a substantially pure or isolated form having a chromatographic purity of greater than 99.5%.

9. A method as claimed in claim 1 , wherein the THCV is administered as a unit dosage of from 0.1 mg to 1000 mg.

10. A method as claimed in claim 2 , wherein the THCV is in a synthetic form.

11. A method as claimed in claim 2 , wherein the THCV is administered together with one or more pharmaceutically acceptable carriers, excipients or diluents.

12. A method as claimed in claim 2 , wherein the THCV is in a substantially pure or isolated form having a chromatographic purity of greater than 95%.

13. A method as claimed in claim 2 , wherein the THCV is in a substantially pure or isolated form having a chromatographic purity of greater than 98%.

14. A method as claimed in claim 2 , wherein the THCV is in a substantially pure or isolated form having a chromatographic purity of greater than 99%.

15. A method as claimed in claim 2 , wherein the THCV is in a substantially pure or isolated form having a chromatographic purity of greater than 99.5%.

Assignees

• Guy Geoffrey William
• Pertwee Roger
• Gw Pharma Ltd

Inventors

• Guy Geoffrey William
• Pertwee Roger

Classifications

• A61P3/04

  Anorexiants; Antiobesity agents · CPC title

• A61K31/00

  Medicinal preparations containing organic active ingredients · CPC title

• A61P25/18

  Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia · CPC title

• A61P25/28

  for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia · CPC title

• A61K31/454

  containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone · CPC title